Onco360® to be specialty pharmacy partner for Karyopharm’s XPOVIO™

Onco360 will be able to support specialized needs of RRMM patients and their physicians across all the U.S. states

The largest independent oncology pharmacy in U.S., Onco360 recently announced that Karyopharm has selected the company as a new specialty pharmacy network partner for its new product XPOVIO, which is a nuclear export inhibitor to be used in combination with dexamethasone to treat adult patients who have relapsed or refractory multiple myeloma (RRMM).

Citing reliable sources, these patients would have received minimum of four previous therapies and whose disease is refractory to minimum two immunomodulatory agents, an anti-CD38 monoclonal antibody and minimum of two proteasome inhibitors.

Paul Jardina, CEO and President at Onco360 said that the company has been selected as the provider of specialty pharmacy for patients with XPOVIO. With the approval of XPOVIO , patients suffering from RRMM who failed prior treatments can have an alternative option. Onco360, being a provider of this major treatment, will be able to support the specialized needs of RRMM patients and their physicians all over the states, Jardina added.

Multiple myeloma involves plasma cells and is an incurable hematological malignancy. Among all patients diagnosed with multiple myeloma, only 50 percent are able to survive more than five years after the initial diagnosis.

According to National Cancer Institute, 30,770 new patients in 2018 had been diagnosed with multiple myeloma in the United States. Reportedly, most patients with multiple myeloma have a relapse after their first complete remission. They often need constant treatment to prevent the disease from progressing. 

Patients suffering from relapsed or refractory multiple myeloma did not have approved products or regimens from the U.S. Food and Drug Administration previously. They often failed their treatment with pomalidomide, carfilzomib, daratumumab and lenalidomide.

Karyopharm Therapeutics manufactures XPOVIO and on July 3  2019 it was approved by the U.S. FDA, based on Phase IIb STORM trial’s positive clinical results. It demonstrated an overall response rate of 21% in patients with heavily-pretreated multiple myeloma.

 

Source Credit- https://www.businesswire.com/news/home/20190703005546/en/Onco360%C2%AE-Selected-Dispense-XPOVIO%E2%84%A2-selinexor